Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)

被引：2
|
作者：
Gutierrez, M. E. [1 ]
Giaccone, G. [2 ]
Liu, S. V. [2 ]
Rajan, A. [3 ]
Guha, U. [3 ]
Halfdanarson, T. R. [4 ]
Curtis, K. K. [5 ]
Kunz, P. L. [6 ]
Gabrail, N. [7 ]
Hinson, J. M. [8 ]
Orlemans, E. O. [9 ]
机构：
[1] John Theurer Canc Ctr, Hematol & Oncol, Hackensack, NJ USA
[2] Georgetown Univ, Lombardi Canc Ctr, Hematol & Oncol, Washington, DC USA
[3] NCI, Thorac & Gastrointestinal Oncol, Ctr Canc Res, Bethesda, MD 20892 USA
[4] Mayo Clin, Med, Rochester, MN USA
[5] Mayo Clin, Internal Med, Scottsdale, AZ USA
[6] Stanford Univ, Sch Med, Med Oncol, Palo Alto, CA 94304 USA
[7] Gabrail Canc Ctr, Hematol, Canton, OH USA
[8] Unicorn Pharma Consulting, Clin Res, Nashville, TN USA
[9] Esanex Inc, Clin Res, Indianapolis, IN USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw369.8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
423PD
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors
    Yao, James C.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan G.
    Resendiz, Karina Hermosillo
    Hu, Ke
    Ravichandran, Shoba
    Strosberg, Jonathan R.
    Wolin, Edward M.
    ONCOTARGETS AND THERAPY, 2017, 10 : 3177 - 3186
  • [22] A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Mazumder, Amitabha
    Chamoun, Kamal
    Karasik, Igor
    Sbar, Eric
    Dugon, Laura
    Tamir, Sharon
    Wang, Xulong
    Prchal, Josef T.
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [24] Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
    Wu, Y.
    Jing, H.
    Zhang, J.
    Cao, X.
    Li, K.
    Liu, Y.
    Meng, M.
    Li, H.
    Kang, W.
    Li, J.
    Wang, Q.
    Zhu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1497 - S1497
  • [25] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [26] Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study
    Altman, Robert D.
    Lang, Anthony E.
    Postuma, Ronald B.
    MOVEMENT DISORDERS, 2011, 26 (13) : 2427 - 2431
  • [27] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
    Ho, A. L.
    Bendell, J. C.
    Cleary, J. M.
    Schwartz, G. K.
    Burris, H. A.
    Oakes, P.
    Agbo, F.
    Barker, P. N.
    Senderowicz, A. M.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
    Desai, Jayesh
    Gan, Hui
    Barrow, Catherine
    Jameson, Michael
    Atkinson, Victoria
    Haydon, Andrew
    Millward, Michael
    Begbie, Stephen
    Brown, Michael
    Markman, Ben
    Patterson, William
    Hill, Andrew
    Horvath, Lisa
    Nagrial, Adnan
    Richardson, Gary
    Jackson, Christopher
    Friedlander, Michael
    Parente, Phillip
    Tran, Ben
    Wang, Lai
    Chen, Yunxin
    Tang, Zhiyu
    Huang, Wendy
    Wu, John
    Zeng, Dewan
    Luo, Lusong
    Solomon, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (19) : 2140 - +
  • [29] Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial
    Naik, Haley B.
    Pichard, Dominique C.
    Schwartz, Daniella M.
    O'Brien, Michelle
    Masciocchi, Matthew
    Thompson, Julie
    Sen, H. Nida
    Steinberg, Seth M.
    Mitchell, Sandra A.
    de Jesus, Adriana A.
    McCalmont, Timothy H.
    Dey, Amit
    Rosenstein, Rachel K.
    Deng, Zuoming
    Goldbach-Mansky, Raphaela
    Mehta, Nehal N.
    Cowen, Edward W.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) : 1380 - 1383
  • [30] A phase Ib/II, open-label, multicenter, dose-escalation and dose-expansion study of NKTR-255 plus cetuximab as a salvage regimen in patients with solid tumors
    Altan, M.
    Patnaik, A.
    Barve, M. A.
    Dunn, L.
    Cobb, P. W.
    Rosenberg, A.
    Sharma, S.
    Sukari, A.
    Lee, Z.
    Marcondes, M. Q.
    Zalevsky, J.
    Tagliaferri, M. A.
    Kotzin, B.
    Sacco, A. G.
    ANNALS OF ONCOLOGY, 2021, 32 : S860 - S861
12345